Mayne Pharma launches BAC capsules

Mayne Pharma is releasing butalbital, acetaminophen and caffeine, or BAC, capsules. The product is indicated for the treatment of migraine.

Mayne Pharma's BAC capsules are available in a dosage strength of 500 mg butalbital, 300 mg acetaminophen and 40 mg of caffeine. 

“This launch complements our existing butalbital product range that includes a variety of dosage forms, strengths and combinations," said Scott Richards, CEO of Mayne Pharma. "Mayne Pharma continues to expand its product portfolio through internal product development, strategic alliances with best-in-class pharmaceutical developers and manufacturers and other business development activities."

BAC capsules 500 mg/300 mg/40 mg had a market value of approximately $40 million for the 12 months ended March 31, 2020, according to IQVIA.